FDA grants fast track designation for Verastem’s NSCLC therapy
The US FDA has granted fast track designation for Verastem’s avutometinib for treating non-small cell lung cancer (NSCLC).
The US FDA has granted fast track designation for Verastem’s avutometinib for treating non-small cell lung cancer (NSCLC).
What's Your Reaction?
